India Pharma Outlook Team | Wednesday, 10 June 2026
EBGLYSS is set to transform the treatment experience for patients living with moderate-to-severe atopic dermatitis after the US Food and Drug Administration (FDA) approved a new extended maintenance dosing schedule.
With the latest approval, eligible patients can now receive EBGLYSS injections once every eight weeks, reducing treatment frequency to as few as six injections annually.
The expanded dosing option marks a significant milestone in eczema care and provides greater convenience for patients seeking long-term disease control.
The approval applies to adults and children aged 12 years and older who weigh at least 88 pounds (40 kg), offering a more flexible treatment regimen without the need for mandatory prescription topical therapies from the start.
According to Eli Lilly and Company, EBGLYSS (lebrikizumab-lbkz) is now the only treatment for moderate-to-severe atopic dermatitis that offers maintenance dosing as infrequently as every eight weeks. The therapy was previously approved for once-monthly maintenance treatment.
Adrienne Brown, president of Lilly Immunology, said the approval builds on the drug's proven long-term durability and provides patients with an option that requires fewer injections while maintaining disease management.
She noted that the new dosing schedule allows patients to experience fewer interruptions from atopic dermatitis and spend less time managing their condition.
Also Read: AI-Augmented Clinical Trials & Drug Development Evolution in India
The FDA's decision was supported by exposure-response modeling and findings from the Phase 3 ADjoin extension study. Researchers evaluated both four-week and eight-week maintenance dosing schedules over a 32-week period.
Peter Lio, author of the ADjoin study and clinical assistant professor of dermatology and pediatrics at Northwestern University, described the approval as an important advancement for individuals living with moderate-to-severe atopic dermatitis.
According to Lio, the extended dosing schedule offers healthcare providers and patients greater flexibility in tailoring treatment plans to individual needs while reducing the burden associated with frequent injections and ongoing disease management.
Safety findings from the 32-week extension study revealed no new safety concerns. Importantly, no patients discontinued treatment because of adverse events during the study period.
The most commonly reported side effects included:
These findings reinforce the established safety profile of EBGLYSS while supporting its use in a less frequent maintenance schedule.
Kristin Belleson, president and CEO of the National Eczema Association, said people with moderate-to-severe atopic dermatitis often face recurring symptoms and time-consuming treatment routines between flare-ups. She emphasized that therapies offering durable disease control with fewer injections can help reduce the daily burden of managing the condition.
EBGLYSS is a monoclonal antibody that specifically targets interleukin-13 (IL-13), a key driver of inflammation associated with atopic dermatitis. The therapy has already received regulatory approvals in several markets, including the United States, European Union, Japan, and Canada.
Outside Europe, Eli Lilly holds global rights to the medicine, while Spanish pharmaceutical company Almirall has licensing rights for dermatology indications across European markets.
Eli Lilly and Company is a global pharmaceutical leader focused on developing innovative medicines across immunology, diabetes, oncology, neuroscience, and other therapeutic areas. The company operates in more than 100 countries and is known for advancing treatments that address significant unmet medical needs.
.jpg)
